Investigations into the aetiopathogenesis of orofacial granulomatosis using multiple omics technologies reveal a potential role for B cells

Maria Tumelty; Krupali Patel; Helen Petersen; Chris Delaney; David Lappin; John Gibson; Gordon Ramage; Christopher van der Gast; Andrew Smith; Christopher John Nile

doi:10.1002/ctm2.70689

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (5) :e70689 DOI: 10.1002/ctm2.70689

LETTER TO THE JOURNAL

Investigations into the aetiopathogenesis of orofacial granulomatosis using multiple omics technologies reveal a potential role for B cells

Author information +

History +

PDF (2991KB)

Keywords

orofacial granulomatosis / B cells / rituximab / proximity extension assay / microbiome

Cite this article

Download citation ▾

Maria Tumelty, Krupali Patel, Helen Petersen, Chris Delaney, David Lappin, John Gibson, Gordon Ramage, Christopher van der Gast, Andrew Smith, Christopher John Nile. Investigations into the aetiopathogenesis of orofacial granulomatosis using multiple omics technologies reveal a potential role for B cells. Clinical and Translational Medicine, 2026, 16 (5) : e70689 DOI:10.1002/ctm2.70689

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Campbell H, Escudier M, Patel P, et al. Distinguishing orofacial granulomatosis from Crohn's disease: two separate disease entities? Inflamm Bowel Dis. 2011; 17(10): 2109-15.

[2]	Mentzer A, Nayee S, Omar Y, et al. Genetic association analysis reveals differences in the contribution of NOD2 variants to the clinical phenotypes of orofacial granulomatosis. Inflamm Bowel Dis. 2016; 22(7): 1552-8.

[3]	Gavioli CFB, Nico MMS, Panajotopoulos N, et al. A case-control study of HLA alleles in Brazilian patients with Melkersson-Rosenthal syndrome. Eur J Med Genet. 2020; 63(7):103879.

[4]	Goel RM, Prosdocimi EM, Amar A, et al. Streptococcus salivarius: a potential salivary biomarker for orofacial granulomatosis and Crohn's disease? Inflamm Bowel Dis. 2019; 25(8): 1367-74.

[5]	Wang Y, Xu H, Wei M, et al. Identification of putative bacterial pathogens for orofacial granulomatosis based on 16S rRNA metagenomic analysis. Microbiol Spectr. 2023; 11(3):e0226622.

[6]	Gale G, Ostman S, Saalman R, Telemo E, Jontell M, Hasséus B. Immunophenotype in orofacial granulomatosis with and without Crohn's disease. Med Oral Patol Oral Cir Bucal. 2014; 19(6): e584-91.

[7]	Liguori S, Musella G, Adamo D, et al. Salivary calprotectin as a biomarker in early onset inflammatory bowel disease: a pilot study. J Clin Med. 2025; 14(12): 4232.

[8]	Chou J, Alazami AM, Jaber F, et al. Hypomorphic variants in AK2 reveal the contribution of mitochondrial function to B-cell activation. J Allergy Clin Immunol. 2020; 146(1): 192-202.

[9]	Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023; 14:1255533.

[10]	Selvaraj S, Priyadarshini A, Muralidhar K, Dennis Joseph L, Swaminathan A. A case of orofacial granulomatosis treated with intravenous rituximab. Cureus. 2025; 17(3):e80123.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.